Benzinga
Benzinga
Benzinga
jueves, septiembre 10

Opus Genetics Inc

IRDNASDAQ
Trade with Public
Trade with Public
$6.07
0.345.93%
al cierre: Sep 10, 5:00 PM EST
$6.03
-0.0439-0.72%
After hour: 4:11 PM EST
PRO
¿Por qué se mueve?:Opus Genetics shares are trading higher after the company announced 3- and ...
Panorámica generalNoticiasPrevisión de beneficiosEventosPrecios objetivoFinanzasSentimientoPropiedadCompararOpcionesInforme de acciones

Opus Genetics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Opus Genetics (IRD).

Price Target Range — 7 Quarters

Analyst Consensus — 16 Analysts

1S.Buy
15Buy
Consensus RatingBuy# Analysts16Avg. Consensus PT$11Upside to Avg. PT+82.5%

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →
DateFirmAnalystActionRating ChangePrice Target
Sep 10, 2026WedbushYun ZhongPT RaiseOutperform$10→$13
Sep 9, 2026Chardan CapitalAndreas ArgyridesPT RaiseBuy$13→$16
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Wedbush Maintains Outperform on Opus Genetics, Raises Price Target to $13

Wedbush analyst Yun Zhong maintains Opus Genetics (NASDAQ:IRD) with a Outperform and raises the price target from $10 to $13.
Benzinga Newsdesk

PRO
Oppenheimer Maintains Outperform on Opus Genetics, Raises Price Target to $20

Oppenheimer analyst Andreas Argyrides maintains Opus Genetics (NASDAQ:IRD) with a Outperform and raises the price target from $10 to $20.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Opus Genetics, Maintains $8 Price Target

HC Wainwright & Co. analyst Matthew Caufield reiterates Opus Genetics (NASDAQ:IRD) with a Buy and maintains $8 price target.
Benzinga Newsdesk

PRO
BTIG Reiterates Buy on Opus Genetics, Maintains $12 Price Target

BTIG analyst Thomas Shrader reiterates Opus Genetics (NASDAQ:IRD) with a Buy and maintains $12 price target.
Benzinga Newsdesk

PRO
RBC Capital Maintains Outperform on Opus Genetics, Lowers Price Target to $9

RBC Capital analyst Lisa Walter maintains Opus Genetics (NASDAQ:IRD) with a Outperform and lowers the price target from $10 to $9.
Benzinga Newsdesk

PRO
TD Cowen Initiates Coverage On Opus Genetics with Buy Rating

TD Cowen analyst Ritu Baral initiates coverage on Opus Genetics (NASDAQ:IRD) with a Buy rating.
Benzinga Newsdesk

Datos y APIs: APIs de Benzinga · API de noticias de acciones · API de calificaciones de analistas · API de logotipos de empresas

Datos de mercado proporcionados por APIs de Benzinga

Benzinga

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

© 2026 Benzinga | All Rights Reserved